NCT04335305 (COPERNICO) is a Phase 2 clinical trial of Tocilizumab in COVID-19, sponsored by MedSIR.

Who is sponsoring NCT04335305?

NCT04335305 is sponsored by MedSIR.

What drugs are being tested in NCT04335305?

Interventions in NCT04335305: Tocilizumab, Pembrolizumab (MK-3475).

What condition does NCT04335305 study?

NCT04335305 studies COVID-19, Pneumonia, Viral.

Is NCT04335305 still recruiting?

NCT04335305 is currently terminated. Last updated 21 June 2022.

Last reviewed 2022-06-21 · How we verify

NCT04335305: COPERNICO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Checkpoint Blockade in COVID-19 Pandemic

Terminated Phase 2 Last updated 21 June 2022

What this trial tests

Phase 2 trial testing Tocilizumab in COVID-19 in 12 participants. Terminated before completion.

Timeline

9 April 2020

Primary endpoint
8 March 2021

21 June 2021

Quick facts

Lead sponsor	MedSIR
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	9 April 2020
Primary completion	8 March 2021
Estimated completion	21 June 2021
Sites	7 locations across Spain

Drugs / interventions tested

Tocilizumab (tocilizumab) — full drug profile →
Pembrolizumab (MK-3475) — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →
Pneumonia, Viral — all drugs for Pneumonia, Viral →

Sponsor

MedSIR — full company profile →

Who can join

Adults 18 to 80, any sex, with COVID-19 or Pneumonia, Viral. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, multicenter, randomized, controlled, open-label, phase 2 clinical trial

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes.
Leisman DE, Ronner L, Pinotti R, Taylor MD, et al · · 2020 · cited 672× · PMID 33075298 · DOI 10.1016/s2213-2600(20)30404-5
The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection.
Copaescu A, Smibert O, Gibson A, Phillips EJ, et al · · 2020 · cited 196× · PMID 32896310 · DOI 10.1016/j.jaci.2020.07.001
COVID-19: Characteristics and Therapeutics.
Chilamakuri R, Agarwal S. · · 2021 · cited 192× · PMID 33494237 · DOI 10.3390/cells10020206
COVID-19 and Cancer: a Comprehensive Review.
Gosain R, Abdou Y, Singh A, Rana N, et al · · 2020 · cited 187× · PMID 32385672 · DOI 10.1007/s11912-020-00934-7
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies.
Market M, Angka L, Martel AB, Bastin D, et al · · 2020 · cited 115× · PMID 32655581 · DOI 10.3389/fimmu.2020.01512
FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2020 · cited 105× · PMID 32717568 · DOI 10.1016/j.drup.2020.100719
Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: Mechanistic insights into current COVID‑19 therapies (Review).
Nitulescu GM, Paunescu H, Moschos SA, Petrakis D, et al · · 2020 · cited 93× · PMID 32468014 · DOI 10.3892/ijmm.2020.4608

Verify or expand the search:

Other trials of Tocilizumab

Trials testing the same drug.

NCT03787290 — Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder · Phase 2 · suspended
NCT07335562 — A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versu · Phase 3 · recruiting
NCT06016517 — Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis · not yet recruiting
NCT06381661 — Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Tra · Phase 2 · not yet recruiting
NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other MedSIR trials

Trials by the same sponsor.

NCT07494448 — Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer · Phase 1, PHASE2 · not yet recruiting
NCT07178938 — Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain Metastases · Phase 2 · not yet recruiting
NCT05708235 — A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population · Phase 2 · recruiting
NCT05659563 — Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10% · Phase 2 · completed
NCT05520723 — Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04335305 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MedSIR
Last refreshed: 21 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04335305.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing